NasdaqGS - Nasdaq Real Time Price USD

ALX Oncology Holdings Inc. (ALXO)

0.4313
-0.0061
(-1.39%)
At close: May 19 at 4:00:01 PM EDT
0.4400
+0.01
+(2.02%)
After hours: May 19 at 7:08:50 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
0
0
0
0
0
Cost of Revenue
--
--
--
0
0
Gross Profit
--
--
--
0
0
Operating Expense
136,525
142,467
170,278
127,436
83,555
Operating Income
-136,525
-142,467
-170,278
-127,436
-83,555
Net Non Operating Interest Income Expense
6,519
7,637
9,084
4,040
78
Other Income Expense
-17
-20
389
-22
-7
Pretax Income
-130,023
-134,850
-160,805
-123,418
-83,484
Tax Provision
--
0
0
64
-21
Net Income Common Stockholders
-130,023
-134,850
-160,805
-123,482
-83,463
Diluted NI Available to Com Stockholders
-130,023
-134,850
-160,805
-123,482
-83,463
Basic EPS
-2.45
--
-3.74
-3.03
-2.07
Diluted EPS
-2.45
--
-3.74
-3.03
-2.07
Basic Average Shares
52,984.5490
--
42,987.7670
40,699.6120
40,308.0500
Diluted Average Shares
52,984.5490
--
42,987.7670
40,699.6120
40,308.0500
Total Operating Income as Reported
-136,525
-142,467
-170,278
-127,436
-83,555
Total Expenses
136,525
142,467
170,278
127,436
83,555
Net Income from Continuing & Discontinued Operation
-130,023
-134,850
-160,805
-123,482
-83,463
Normalized Income
-130,023
-134,850
-160,805
-123,482
-83,463
Interest Income
8,227
9,366
10,649
4,278
91
Interest Expense
1,708
1,729
1,565
238
13
Net Interest Income
6,519
7,637
9,084
4,040
78
EBIT
-128,315
-133,121
-159,240
-123,180
-83,471
EBITDA
-127,446
-132,249
-158,404
-122,838
-83,420
Reconciled Cost of Revenue
--
--
--
0
0
Reconciled Depreciation
869
872
836
342
51
Net Income from Continuing Operation Net Minority Interest
-130,023
-134,850
-160,805
-123,482
-83,463
Total Unusual Items Excluding Goodwill
--
--
--
0
0
Total Unusual Items
--
--
--
0
0
Normalized EBITDA
-127,446
-132,249
-158,404
-122,838
-83,420
Tax Rate for Calcs
0
0
0
0.0002
0
Tax Effect of Unusual Items
0
0
0
0
0
12/31/2021 - 7/17/2020

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

GBIO Generation Bio Co.
0.4018
+5.38%
 
FDMT 4D Molecular Therapeutics, Inc.
3.8000
+10.47%
 
NKTX Nkarta, Inc.
1.7000
-2.30%
 
ZNTL Zentalis Pharmaceuticals, Inc.
1.2500
-0.79%
 
IPSC Century Therapeutics, Inc.
0.5543
-1.02%
 
PMVP PMV Pharmaceuticals, Inc.
0.8740
+0.94%
 
PASG Passage Bio, Inc.
0.2980
-1.32%
 
VTYX Ventyx Biosciences, Inc.
1.4500
+3.57%
 
OLMA Olema Pharmaceuticals, Inc.
4.8000
+1.91%
 
IKNA Ikena Oncology, Inc.
1.1100
0.00%